Medical treatment in acromegaly: a network meta-analysis
Our findings suggest pasireotide LAR and pegvisomant as the most effective treatments for IGF-1 normalization. Pasireotide LAR was the best treatment for tumor shrinkage, though the evidence base was limited, requiring cautious interpretation. Their potential role as first-line options after surgery requires further research. Clinical decisions should consider cost, safety, and patient-specific parameters to optimize outcomes.
Authors
- Mirela Diana Ilie (ORCID: https://orcid.org/0000-0001-7248-7258)
- Dario De Alcubierre (ORCID: https://orcid.org/0000-0001-5242-1761)
- Dimitrios G. Goulis (ORCID: https://orcid.org/0000-0002-5005-1995)
- Gérald Raverot (ORCID: https://orcid.org/0000-0002-9517-338X)
- Panagiotis Anagnostis (ORCID: https://orcid.org/0000-0002-8949-4312)
- Olaf M. Dekkers (ORCID: https://orcid.org/0000-0002-1333-7580)
- Chrysi Kaparounaki (ORCID: https://orcid.org/0000-0002-0400-4063)
- Anna‐Bettina Haidich (ORCID: https://orcid.org/0000-0001-5100-8799)
- Andrea Maria Isidori (ORCID: https://orcid.org/0000-0002-9037-5417)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Lyon College (US)
- Aristotle University of Thessaloniki (GR)
- Leiden University Medical Center (NL)
- Communauté urbaine de Lyon (FR)
- Laboratoire National de Référence (MA)
- Institutul Național de Endocrinologie C.I. Parhon (RO)
- Centre de Recherche en Cancérologie de Lyon (FR)
- ERN GUARD-Heart (NL)
- Institut National des Sciences Appliquées de Lyon (FR)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- European Journal of Endocrinology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1093/ejendo/lvaf221
- Citations
- 1
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.29